- We are
Spark - Our scientific
platform & programs - Patients
& families - Healthcare
professionals -
Investors
& media - Join the
Spark team
Our Scientific Platform and Programs
Spark Therapeutics has built a leading integrated gene therapy platform as we strive to turn genes into medicines for patients with inherited diseases, including inherited retinal diseases (IRDs), liver-mediated diseases such as hemophilia, and neurodegenerative diseases. Learn more about our platform below.
Cutting-edge vector
design
We are advancing research programs against cell targets in the retina, liver and central nervous system using adeno-associated viral (AAV) vectors. Our viral vectors are designed to encapsulate genetic material for the potential treatment of genetic diseases. The vectors used in our research programs have been engineered using Spark’s cutting-edge proprietary platform, selected through vigorous preclinical testing and validated in several clinical trials.
State-of-the-art, in-house expertise in vector manufacturing
With adeno-associated viral (AAV) vector manufacturing capabilities in-house, investigational clinical-grade vectors developed and manufactured by our team have been delivered through six routes of administration to hundreds of patients in more than a dozen clinical trials.
Innovative scientific and regulatory strategies
We work in a spirit of collaboration with investigators and regulators to develop rigorous and novel endpoints that measure the potential impact of our investigational, potentially one-time therapies on targeted diseases and to help shape high standards for future gene therapies. At the forefront of gene therapy research for more than two decades, members of our scientific team are responsible for numerous development milestones, including the first clinical trials of adeno-associated viral (AAV) vectors in skeletal muscle tissue and the liver; the first clinical studies to evaluate AAV administration to the second eye; and the first gene therapy trial for a non-lethal disorder that included pediatric participants.
Strong commitment to improve patient care
We are committed to developing an approach to patient access tailored to the unique nature of an investigational, potentially one-time, life-altering gene therapy. We are providing education and other resources to promote a shift from clinical to genetic-based disease classification, and advocating for patient access to care and incentives for innovation.
Pipeline
Spark Therapeutics is working to address a range of debilitating genetic diseases, including inherited retinal diseases (IRDs), liver-mediated diseases and neurodegenerative diseases. Each of our investigational research programs uses an adeno-associated viral (AAV) vector developed and manufactured by the Spark team and our collaborators.
INHERITED RETINAL DISEASES (IRDs)
PRECLINICAL
PHASE 1 / 2
PHASE 3
REGISTRATION
LUXTURNA™ (voretigene neparvovec): biallelic RPE65-mediated IRD
PHASE 3
SPK-7001: Choroideremia
PHASE 1/2
RHO-adRP
PRECLINICAL
Leber hereditary optic neuropathy (LHON)
PRECLINICAL
P-SPK-ALL-790055
Spark Therapeutics, Inc.
3737 Market Street
Philadelphia, PA 19104
Phone: 1-855-SPARKTX / +1 215-220-9300
